Axolabs
Private Company
Funding information not available
Overview
Axolabs is a privately held, full-service CRO/CDMO focused exclusively on the oligonucleotide and RNA therapeutics sector. The company leverages over two decades of legacy expertise from pioneers like Ribopharma, Alnylam, and Roche to offer a seamless, 'discovery-to-clinic' pathway for its biopharma and academic clients. With dual-site manufacturing capabilities in Germany and the USA, Axolabs provides critical services in bioinformatics-driven design, high-throughput screening, process development, and scalable GMP production. Its integrated model positions it as a key enabler in the rapidly growing field of RNA-targeted medicines.
Technology Platform
Integrated CRO/CDMO platform for oligonucleotides featuring proprietary bioinformatics-driven sequence design, high-throughput screening, solid-phase synthesis, GLP bioanalysis, and scalable GMP manufacturing using Cytiva and Asahi Kasei Bioprocess systems.
Opportunities
Risk Factors
Competitive Landscape
Axolabs competes in the oligonucleotide CRO/CDMO space against large, diversified contract manufacturers (e.g., Lonza, Catalent, Thermo Fisher Scientific) that have invested in oligonucleotide capabilities, as well as other specialized firms like Eurogentec, LGC Biosearch Technologies, and Nitto Denko Avecia. Its key differentiators are its pure-play focus, integrated discovery-to-clinic services, and legacy expertise from RNAi industry pioneers.